libvenerstat

Libvenerstat (SAF312A) is a potent, selective, and orally bioavailable small molecule antagonist of the Transient Receptor Potential Ankyrin 1 (TRPA1) channel. Developed by Novartis, it is designed to target TRPA1 receptors located on sensory nerve endings, which play a crucial role in detecting noxious stimuli and mediating inflammatory pain and the cough reflex. By blocking these channels, libvenerstat aims to treat conditions characterized by neuronal hypersensitivity, such as refractory or unexplained chronic cough and acute post-operative pain. Clinical development has focused on its potential to provide a non-opioid alternative for pain management and a novel mechanism for cough suppression by reducing the hypersensitivity of the cough reflex arc.

Other names

libvenerstat